Laboratory study suggests that thalidomide-like drugs could be designed to target a broad array of transcription factors, and open a new landscape of cancer drug development.
In explaining why mutations in the gene TP53 tend to cluster in “hot spots,” a new study lays the groundwork for ability to identify the function of any mutation in any cancer gene.